Dyadic's C1-made RSV and malaria antibodies move into animal studies
Dyadic said the Gates Medical Research Institute has started preclinical mouse studies of antibodies made on its C1 platform against RSV and malaria.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dyadic International said the Gates Medical Research Institute has begun preclinical animal studies. The mouse experiments compare antibodies against respiratory syncytial virus (RSV) and malaria made on Dyadic's C1 platform with versions produced in the CHO mammalian cells used in conventional manufacturing.
Four groups of mice are being tested to assess the pharmacokinetics of the RSV antibody RSM01 and the malaria antibody MAM01. Results are expected in the first quarter of 2027. The company reported yields of about 12.1 g/L for RSM01 and 13.2 g/L for MAM01 in seven-day fermentation runs.
why it matters
This story concerns biotechnology and has no link to cryptocurrency mining. For markets it is an early preclinical step: the results do not yet show the platform's commercial potential, and the release contains no financial figures for the company.
tags
instruments
sources
- Dyadic’s C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations — globenewswire.com, 12 November 2026 at 12:30 UTC
- Dyadic’s C1-Produced RSV And Malaria Antibodies Advance Into Animal Studies Following Positive Independent Evaluations — Reuters, 12 November 2026 at 13:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗